Renaissance Technologies
ACET icon

Renaissance Technologies’s Adicet Bio ACET Stock Holding History

Renaissance Technologies’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
265,945
+33,354
+14% +$263K ﹤0.01% 1876
2026
Q1 		$1.58M Sell
232,591
-10,354
-4% -$77.5K ﹤0.01% 2019
2025
Q4 		$2.05M Buy
242,945
+128,636
+113% +$1.42M ﹤0.01% 1847
2025
Q3 		$1.48M Buy
114,309
+42,195
+59% +$497K ﹤0.01% 2267
2025
Q2 		$704K Buy
72,114
+21,445
+42% +$226K ﹤0.01% 2670
2025
Q1 		$612K Sell
50,669
-6,612
-12% -$94.5K ﹤0.01% 2655
2024
Q4 		$882K Sell
57,281
-19,694
-26% -$372K ﹤0.01% 2562
2024
Q3 		$1.77M Sell
76,975
-17,563
-19% -$393K ﹤0.01% 2103
2024
Q2 		$1.83M Buy
94,538
+28,975
+44% +$776K ﹤0.01% 1929
2024
Q1 		$2.46M Buy
65,563
+17,650
+37% +$730K ﹤0.01% 1893
2023
Q4 		$1.45M Buy
47,913
+5,600
+13% +$122K ﹤0.01% 2162
2023
Q3 		$927K Buy
42,313
+29,163
+222% +$1.03M ﹤0.01% 2360
2023
Q2 		$511K Sell
13,150
-6,588
-33% -$581K ﹤0.01% 2859
2023
Q1 		$1.82M Buy
19,738
+17,882
+963% +$2.24M ﹤0.01% 2086
2022
Q4 		$266K Buy
+1,856
New +$463K ﹤0.01% 3277
2022
Q3 		– Sell
-7,844
Closed -$1.83M – 3980
2022
Q2 		$1.83M Buy
+7,844
New +$1.72M ﹤0.01% 2249
2021
Q4 		– Sell
-2,639
Closed -$331K – 3864
2021
Q3 		$331K Sell
2,639
-2,467
-48% -$306K ﹤0.01% 3049
2021
Q2 		$841K Buy
5,106
+3,850
+307% +$784K ﹤0.01% 2754
2021
Q1 		$263K Buy
+1,256
New +$288K ﹤0.01% 3094

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Renaissance Technologies's ACET Position: Q2 2026 in Review

Renaissance Technologies increased its Adicet Bio (ACET) stake by 14% in Q2 2026, buying an estimated $263K and bringing the position to 265,945 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Renaissance Technologies first reported a position in ACET in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.46M in Q1 2024. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Renaissance Technologies held 265,945 shares of Adicet Bio worth $2.3M as of Q2 2026.
  • Renaissance Technologies bought 33,354 Adicet Bio shares in Q2 2026, an estimated $263K.
  • Adicet Bio made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1876 holding.
  • Renaissance Technologies first reported a position in Adicet Bio in Q1 2021 and has held it in 19 quarters since.
  • Renaissance Technologies's Adicet Bio position peaked at $2.46M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.